Andrzej Dlugosz to oversee basic science research at Rogel Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Andrzej Dlugosz was named associate director for basic science research at the University of Michigan Rogel Cancer Center.

Dlugosz is the Poth Professor of Cutaneous Oncology and professor of dermatology and of cell and developmental biology at the University of Michigan. He co-leads the Rogel Cancer Center’s cancer biology program.

In his new role, Dlugosz will oversee the Rogel Cancer Center’s four basic science research programs, which focus on cancer biology, genetics, developmental therapeutics and immunology.

Dlugosz joined the faculty at the University of Michigan in 1997 and currently serves as associate chair for research in the Department of Dermatology.

His research focuses on how alterations in the Hedgehog signaling pathway contribute to cancer initiation, progression and maintenance in tumors arising in the skin and other organs. In more recent studies, he has also been investigating the molecular underpinnings of Merkel cell carcinoma.

Dlugosz replaces Stephen Weiss, who stepped down to build on his laboratory research efforts. Dlugosz’ appointment is effective Nov. 1.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login